Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011 (2011), Article ID 485471, 9 pages
http://dx.doi.org/10.1093/ecam/neq066
Original Article

Ameliorate Effects of Li-Fu Formula on IL-6-Mediated Cardiac Hypertrophy in Hamsters Fed with a Hyper-Cholesterol Diet

1Emergency Department of Taichung Veterans General Hospital, China Medical University, Taiwan
2Department of Biological Science and Technology, China Medical University, Taiwan
3Graduate Institute of Basic Medical Science, China Medical University, Taiwan
4Department of Food and Nutrition, Huang-Kuang University, Taiwan
5Graduate Institute of Chinese Medical Science, China Medical University, Taiwan
6Department of Pediatrics, Medical Research and Medical Genetics, China Medical College Hospital, Taiwan
7Department of Healthcare Administration, Asia University, Taiwan
8Department of Health and Nutrition Biotechnology, Asia University, Taiwan
9Institute of Immunology, School of Medicine, Chung Shan Medical University, Taichung, Taiwan No. 110, Sec. 1, Jianguo N. Road, Taichung 402, Taiwan
10Clinical Laboratory, School of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. No. 110, Sec. 1, Jianguo N. Road, Taichung 402, Taiwan
11Department of Biochemistry, School of Medicine, Chung Shan Medical University, Taichung, Taiwan. No. 110, Sec. 1, Jianguo N. Road, Taichung 402, Taiwan
12Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan. No. 110, Sec. 1, Jianguo N. Road, Taichung 402, Taiwan

Received 11 March 2010; Accepted 13 May 2010

Copyright © 2011 Yi-Chang Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. J. Harjai, “Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen,” Annals of Internal Medicine, vol. 131, no. 5, pp. 376–386, 1999. View at Google Scholar · View at Scopus
  2. G. W. Dorn II and H. S. Hahn, “Genetic factors in cardiac hypertrophy,” Annals of the New York Academy of Sciences, vol. 1015, pp. 225–237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Wakatsuki, J. Schlessinger, and E. L. Elson, “The biochemical response of the heart to hypertension and exercise,” Trends in Biochemical Sciences, vol. 29, no. 11, pp. 609–617, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. N. S. Dhalla, A. Ziegelhoffer, P. K. Singal, V. Panagia, and K. S. Dhillon, “Subcellular changes during cardiac hypertrophy and heart failure due to bacterial endocarditis,” Basic Research in Cardiology, vol. 75, pp. 81–91, 1980. View at Google Scholar
  5. A. M. Gotto Jr., “Heart disease in the assessment and treatment of hypercholesterolemia: coronary artery disease and other atherosclerotic disease, family history, and left ventricular hypertrophy,” American Journal of Medicine, vol. 96, pp. 9S–18S, 1994. View at Google Scholar
  6. Q. M. Chen, V. C. Tu, S. Purdon, J. Wood, and T. Dilley, “Molecular mechanisms of cardiac hypertrophy induced by toxicants,” Cardiovascular Toxicology, vol. 1, no. 4, pp. 267–283, 2001. View at Google Scholar · View at Scopus
  7. S. Zhang, M. H. Picard, E. Vasile et al., “Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice,” Circulation, vol. 111, no. 25, pp. 3457–3464, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Itoh and K. Nakao, “Natriuretic peptide system,” Nippon Rinsho, vol. 55, pp. 1923–1936, 1997. View at Google Scholar
  9. S. J. Cameron, S. Itoh, C. P. Baines et al., “Activation of big MAP kinase 1 (BMK1/ERK5) inhibits cardiac injury after myocardial ischemia and reperfusion,” FEBS Letters, vol. 566, pp. 255–260, 2004. View at Google Scholar
  10. A. Luchner, T. L. Stevens, D. D. Borgeson et al., “Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure,” American Journal of Physiology, vol. 274, no. 5, pp. H1684–H1689, 1998. View at Google Scholar · View at Scopus
  11. H. Kawakami, H. Okayama, M. Hamada, and K. Hiwada, “Alteration of atrial natriuretic peptide and brain natriuretic peptide gene expression associated with progression and regression of cardiac hypertrophy in renovascular hypertensive rats,” Clinical Science, vol. 90, pp. 197–204, 1996. View at Google Scholar
  12. Y. Saito, K. Nakao, H. Arai et al., “Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart,” Journal of Clinical Investigation, vol. 83, no. 1, pp. 298–305, 1989. View at Google Scholar · View at Scopus
  13. B. Swynghedauw, “Molecular mechanisms of myocardial remodeling,” Physiological Reviews, vol. 79, no. 1, pp. 215–262, 1999. View at Google Scholar · View at Scopus
  14. T. Kanda and T. Takahashi, “Interleukin-6 and cardiovascular diseases,” Japanese Heart Journal, vol. 45, no. 2, pp. 183–193, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Takahashi, X. Ouyang, K. Komatsu et al., “Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells,” Biochemical Pharmacology, vol. 64, pp. 745–749, 2002. View at Google Scholar
  16. T. Hirano, “Interleukin 6 and its receptor: ten years later,” International Reviews of Immunology, vol. 16, no. 3-4, pp. 249–284, 1998. View at Google Scholar · View at Scopus
  17. H. Kodama, K. Fukuda, J. Pan et al., “Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes,” Circulation Research, vol. 81, no. 5, pp. 656–663, 1997. View at Google Scholar · View at Scopus
  18. H. Hirota, K. Yoshida, T. Kishimoto, and T. Taga, “Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 11, pp. 4862–4866, 1995. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Ogata, N. Nishimoto, and K. Yoshizaki, “Advances in interleukin-6 therapy,” Rinsho Byori, vol. 47, no. 4, pp. 321–326, 1999. View at Google Scholar · View at Scopus
  20. K. Kunisada, E. Tone, Y. Fujio, H. Matsui, K. Yamauchi-Takihara, and T. Kishimoto, “Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes,” Circulation, vol. 98, no. 4, pp. 346–352, 1998. View at Google Scholar · View at Scopus
  21. D. C. H. Ng, N. W. Court, C. G. Dos Remedios, and M. A. Bogoyevitch, “Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts,” Cardiovascular Research, vol. 57, no. 2, pp. 333–346, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. R. L. Nicol, N. Frey, G. Pearson, M. Cobb, J. Richardson, and E. N. Olson, “Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy,” EMBO Journal, vol. 20, no. 11, pp. 2757–2767, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Takano, Y. Zou, H. Akazawa et al., “Inhibitory molecules in signal transduction pathways of cardiac hypertrophy,” Hypertension Research, vol. 25, no. 4, pp. 491–498, 2002. View at Google Scholar · View at Scopus
  24. C. Ruwhof and A. Van Der Laarse, “Mechanical stress-induced cardiac hypertrophy: Mechanisms and signal transduction pathways,” Cardiovascular Research, vol. 47, no. 1, pp. 23–37, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. T. L. Wadsworth, T. L. McDonald, and D. R. Koop, “Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced signaling pathways involved in the release of tumor necrosis factor-alpha,” Biochemical Pharmacology, vol. 62, pp. 963–974, 2001. View at Google Scholar
  26. Y. K. Yim, H. Lee, K. E. Hong et al., “Anti-inflammatory and immune-regulatory effects of subcutaneous Perillae fructus extract injections on OVA-induced asthma in mice,” Evidence-Based Complementary and Alternative Medicine, vol. 7, pp. 79–86, 2010. View at Google Scholar
  27. T. W. Wu, L. H. Zeng, K. P. Fung et al., “Effect of sodium tanshinone IIA sulfonate in the rabbit myocardium and on human cardiomyocytes and vascular endothelial cells,” Biochemical Pharmacology, vol. 46, pp. 2327–2332, 1993. View at Google Scholar
  28. L. Yang, X. Zou, Q. Liang et al., “Sodium tanshinone IIA sulfonate depresses angiotensin II-induced cardiomyocyte hypertrophy through MEK/ERK pathway,” Experimental and Molecular Medicine, vol. 39, pp. 65–73, 2007. View at Google Scholar
  29. L. W. Qi, Q. T. Yu, P. Li et al., “Quality evaluation of Radix Astragali through a simultaneous determination of six major active isoflavonoids and four main saponins by high-performance liquid chromatography coupled with diode array and evaporative light scattering detectors,” The Journal of Chromatography A, vol. 1134, pp. 162–169, 2006. View at Google Scholar
  30. Y. H. Shon, J. H. Kim, and K. S. Nam, “Effect of Astragali radix extract on lipopolysaccharide-induced inflammation in human amnion,” Biological & Pharmaceutical Bulletin, vol. 25, no. 1, pp. 77–80, 2002. View at Google Scholar · View at Scopus
  31. I. M. Liu, T. F. Tzeng, and S. S. Liou, “A Chinese herbal decoction, Dang Gui Bu Xue Tang, prepared from Radix Astragali and Radix Angelicae sinensis, Ameliorates insulin resistance induced by a high-fructose diet in rats,” Evidence-Based Complementary and Alternative Medicine, 2009. View at Publisher · View at Google Scholar
  32. X.-J. Chen, Z.-P. Bian, S. Lu et al., “Cardiac protective effect of Astragalus on viral myocarditis mice: comparison with Perindopril,” American Journal of Chinese Medicine, vol. 34, no. 3, pp. 493–502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Takahashi, X. Ouyang, K. Komatsu et al., “Sodium tanshinone IIA sulfonate derived from Danshen (Salvia miltiorrhiza) attenuates hypertrophy induced by angiotensin II in cultured neonatal rat cardiac cells,” Biochemical Pharmacology, vol. 64, pp. 745–749, 2002. View at Google Scholar
  34. J. D. Adams Jr., M. Wall, and C. Garcia, “Salvia columbariae contains tanshinones,” Evidence-Based Complementary and Alternative Medicine, vol. 2, no. 1, pp. 107–110, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. W.-W. Kuo, T.-C. Hsu, M.-H. Chain et al., “Attenuated cardiac mitochondrial-dependent apoptotic effects by Li-Fu formula in hamsters fed with a hypercholesterol diet,” Evidence-Based Complementary and Alternative Medicine, 2009. View at Publisher · View at Google Scholar
  36. N. P. Visavadiya and A. V. R. L. Narasimhacharya, “Asparagus root regulates cholesterol metabolism and improves antioxidant status in hypercholesteremic rats,” Evidence-Based Complementary and Alternative Medicine, vol. 6, no. 2, pp. 219–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Vojdani, J. Lambert, and G. Kellermann, “The role of Th17 in neuroimmune disorders: a target for CAM therapy. Part III,” Evidence-Based Complementary and Alternative Medicine, 2009. View at Publisher · View at Google Scholar
  38. R. Patel, D.-S. Lim, D. Reddy et al., “Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy,” Journal of Molecular and Cellular Cardiology, vol. 32, no. 12, pp. 2369–2377, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. C. D. Egan, “Addressing use of herbal medicine in the primary care setting,” Journal of the American Academy of Nurse Practitioners, vol. 14, no. 4, pp. 166–171, 2002. View at Google Scholar · View at Scopus
  40. E. L. Cooper, “Drug discovery, CAM and natural products,” Evidence-Based Complementary and Alternative Medicine, vol. 1, pp. 215–217, 2004. View at Google Scholar
  41. E. L. Cooper, “CAM, eCAM, bioprospecting: the 21st century pyramid,” Evidence-Based Complementary and Alternative Medicine, vol. 2, no. 2, pp. 125–127, 2005. View at Publisher · View at Google Scholar · View at Scopus